 |
|
|
|
 |
|
|
 Contact |  Print version |  PDF version |  Send article |  RSS-Feed
Independent Results Support the Use of BioCurex Technology for Gastric Cancer19 Oct 2006 -
BioCurex Inc. announced that a group of scientists led by Dr. So Tsuboi from the Shigei Medical Research Hospital, Japan, have published results on the expression of the receptor for AFP (RECAF) in normal, benign and malignant stomach tissue. The tissue study used a variation of the company's Histo-RECAF kit. The results indicate that RECAF was expressed in 34 out of 47 cancers and not expressed in 59 out of 61 normal or benign tissues. The authors conclude that RECAF may become a new clinically useful marker of gastric cancer. The paper was published in Tumor Biology.
The other institutions involved in this study were the Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, the Okayama Citizen's Hospital, and the Oota Memorial Hospital, Fukuyama.
Additional information
BioCurex, Inc.
Richmond, BC, Canada
Company
News
|
|
|
|
|
|
Top